NBIX
Neurocrine Biosciences, Inc.
113.59
USD
This page is just a preview of the data found in TrendSpider’s full version
Neurocrine Biosciences, Inc. stock is up 2.39% since 30 days ago. The next earnings date is Feb 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 27 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 15% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 24 Oct 13:44 | 17 Nov, 2023 | 105.00 | 848 | ||
| 24 Oct 13:44 | 17 Nov, 2023 | 105.00 | 848 | ||
| 24 Oct 13:44 | 17 Nov, 2023 | 105.00 | 848 | ||
| 24 Oct 13:44 | 17 Nov, 2023 | 105.00 | 848 | ||
| 24 Oct 14:14 | 17 Nov, 2023 | 105.00 | 848 | ||
| 24 Oct 14:14 | 17 Nov, 2023 | 105.00 | 848 | ||
| 02 Nov 15:19 | 17 Nov, 2023 | 50.00 | 4 | ||
| 07 Nov 20:35 | 19 Jan, 2024 | 120.00 | 374 | ||
| 16 Nov 18:21 | 19 Jan, 2024 | 115.00 | 13 | ||
| 16 Nov 20:11 | 15 Dec, 2023 | 105.00 | 1953 |
Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.
